The success of immune checkpoint blockade (ICB) therapies, such as antibodies targeting PD-1, PD-L1, and CTLA-4, is critically dependent on the presence of a pre-existing T-cell infiltrate within the tumor, as tumors lacking this infiltrate are typically resistant to ICB [198,199]. This evidence concerns the gene CTLA4 and neoplasm.